Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review
Open accessThe DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Stimulant drugs are second only to cannabis as the most widely used class of illicit drug globally, accounting for 68 million past-year consumers. Dependence on amphetamines (AMPH) or methamphetamine (MA) is a growing global concern. Yet, there is no established pharmacotherapy for AMPH/MA dependence. A comprehensive assessment of the research literature on pharmacotherapy for AMPH/MA dependence may inform treatment guidelines and future research directions. METHODS: We systematically reviewed the peer-reviewed literature via the electronic databases PubMed, EMBASE, CINAHL and SCOPUS for randomised controlled trials reported in the English language examining a pharmacological treatment for AMPH/MA dependence or use disorder. We included all studies published to 19 June 2019. The selected studies were evaluated for design; methodology; inclusion and exclusion criteria; sample size; pharmacological and (if included) psychosocial interventions; length of follow-up and follow-up schedules; outcome variables and measures; results; overall conclusions and risk of bias. Outcome measures were any reported impact of treatment related to AMPH/MA use. RESULTS: Our search returned 43 studies that met our criteria, collectively enrolling 4065 participants and reporting on 23 individual pharmacotherapies, alone or in combination. Disparate outcomes and measures (n = 55 for the primary outcomes) across studies did not allow for meta-analyses. Some studies demonstrated mixed or weak positive signals (often in defined populations, e.g. men who have sex with men), with some variation in efficacy signals dependent on baseline frequency of AMPH/MA use. The most consistent positive findings have been demonstrated with stimulant agonist treatment (dexamphetamine and methylphenidate), naltrexone and topiramate. Less consistent benefits have been shown with the antidepressants bupropion and mirtazapine, the glutamatergic agent riluzole and the corticotropin releasing factor (CRF-1) antagonist pexacerfont; whilst in general, antidepressant medications (e.g. selective serotonin reuptake inhibitors [SSRIs], tricyclic antidepressants [TCAs]) have not been effective in reducing AMPH/MA use. CONCLUSIONS: No pharmacotherapy yielded convincing results for the treatment of AMPH/MA dependence; mostly studies were underpowered and had low treatment completion rates. However, there were positive signals from several agents that warrant further investigation in larger scale studies; agonist therapies show promise. Common outcome measures should include change in use days. Future research must address the heterogeneity of AMPH/MA dependence (e.g. coexisting conditions, severity of disorder, differences between MA and AMPH dependence) and the role of psychosocial intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Bupropion has been shown to reduce nicotine/tobacco use in patients who smoke cigarettes or use other nicotine/tobacco products.109”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the current body of evidence supporting prescription stimulants for treating stimulant use disorders remains inconclusive [58,66,67,68,69].”
From Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review (2024) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Demand for treatment is increasing globally [4]; however, there are currently no approved pharmacotherapies, despite extensive research investigating potential candidates [6][7][8].”
From Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study. (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are no robustly effective pharmacotherapies available (6)”
From Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use (2024) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“which is encouraging, given the dropout rates of around 40% in prior studies of MAUD treatments [8].”
From Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study. (2025) · cites this paper as [8]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Encyclopedia of the Neurological Sciences · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,117
CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group* (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-11-201006010-00232 · Cited by 3,824
Neurobiology of addiction: a neurocircuitry analysis
Koob, G. F., & Volkow, N. D. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)00104-8 · Cited by 3,698
International Statistical Classification of Diseases and Related Health Problems
Eisfeld, J. (2014) · TSQ: Transgender Studies Quarterly · doi:10.1215/23289252-2399740 · Cited by 3,570
White, J. M. L., Kita, M., Krpelanová, E., Alsokhn, C., Costa, M. L., Fibbe, W., Gaebel, W., Reed, G. M., Lokuhetty, D., Woolf, A., et al. (2026) · Bulletin of the World Health Organization · doi:10.2471/blt.25.294650 · Cited by 832
Major physical and psychological harms of methamphetamine use
DARKE, S., KAYE, S., McKETIN, R., & DUFLOU, J. (2008) · Drug and Alcohol Review · doi:10.1080/09595230801923702 · Cited by 675
Implications of Chronic Methamphetamine Use: A Literature Review
Meredith, C. W., Jaffe, C., Ang-Lee, K., & Saxon, A. J. (2005) · Harvard Review of Psychiatry · doi:10.1080/10673220591003605 · Cited by 393
Shoptaw, S., Reback, C. J., Peck, J. A., Yang, X., Rotheram-Fuller, E., Larkins, S., Veniegas, R. C., Freese, T. E., & Hucks-Ortiz, C. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.10.004 · Cited by 313
Responding to global stimulant use: challenges and opportunities
Farrell, M., Martin, N. K., Stockings, E., Bórquez, A., Cepeda, J. A., Degenhardt, L., Ali, R., Tran, L. T., Rehm, J., Torrens, M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32230-5 · Cited by 310
De Crescenzo, F., Ciabattini, M., D’Alò, G. L., De Giorgi, R., Del Giovane, C., Cassar, C., Janiri, L., Clark, N., Ostacher, M. J., & Cipriani, A. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002715 · Cited by 274
Methamphetamine Psychosis: Epidemiology and Management
Glasner-Edwards, S., & Mooney, L. J. (2014) · CNS Drugs · doi:10.1007/s40263-014-0209-8 · Cited by 266
A systematic review of cognitive and behavioural therapies for methamphetamine dependence
LEE, N. K., & RAWSON, R. A. (2008) · Drug and Alcohol Review · doi:10.1080/09595230801919494 · Cited by 255
Corticotropin releasing factor: A key role in the neurobiology of addiction
Zorrilla, E. P., Logrip, M. L., & Koob, G. F. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.01.001 · Cited by 254
GABAB receptor agonists for the treatment of drug addiction: a review of recent findings
Cousins, M. S., Roberts, D. C. S., & Wit, H. D. (2002) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(01)00163-6 · Cited by 240
Rawson, R. A., McCann, M. J., Flammino, F., Shoptaw, S., Miotto, K., Reiber, C., & Ling, W. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01312.x · Cited by 238
Bupropion for the treatment of methamphetamine dependence
Elkashef, A. M., Rawson, R. A., Anderson, A. L., Li, S.-H., Holmes, T., Smith, E. V., Chiang, N., Kahn, R., Vocci, F., Ling, W., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301481 · Cited by 234
Gender and use of substance abuse treatment services.
Green, C. A. (2006) · PubMed Central · Cited by 230
The Potential for Misuse and Abuse of Medications in ADHD: A Review
Clemow, D. B., & Walker, D. J. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.09.2801 · Cited by 198
Naltrexone for the Treatment of Amphetamine Dependence: A Randomized, Placebo-Controlled Trial
Jayaram-Lindström, N., Hammarberg, A., Beck, O., & Franck, J. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08020304 · Cited by 185
A Comparison of Aripiprazole, Methylphenidate, and Placebo for Amphetamine Dependence
Tiihonen, J., Kuoppasalmi, K., Föhr, J., Tuomola, P., Kuikanmäki, O., Vorma, H., Sokero, P., Haukka, J., & Meririnne, E. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.1.160 · Cited by 178
Mirtazapine to Reduce Methamphetamine Use: A Randomized Controlled Trial
Colfax, G. N. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.124 · Cited by 175
Global patterns of methamphetamine use
Chomchai, C., & Chomchai, S. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000168 · Cited by 170
Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence
SHOPTAW, S. J., Heinzerling, K. G., Rotheram-Fuller, E. J., Steward, T., Wang, J., Swanson, A., Garza, R. D. L., Newton, T., & Ling, W. W. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.03.010 · Cited by 169
A double‐blind, placebo‐controlled trial of modafinil (200 mg/day) for methamphetamine dependence
Shearer, J., Darke, S., Rodgers, C., Slade, T., Van Beek, I., Lewis, J., Brady, D., McKetin, R., Mattick, R. P., & Wodak, A. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02437.x · Cited by 159
SHOPTAW, S. J., Huber, A., Peck, J. A., Yang, X., Liu, J., Dang, J., Roll, J. M., Shapiro, B., Rotheram-Fuller, E. J., & Ling, W. W. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.03.005 · Cited by 149
McKetin, R., Najman, J. M., Baker, A. L., Lubman, D. I., Dawe, S., Ali, R., Lee, N. K., Mattick, R. P., & Mamun, A. (2012) · Addiction · doi:10.1111/j.1360-0443.2012.03933.x · Cited by 147
The acute effects of d-amphetamine and methamphetamine on attention and psychomotor performance
Silber, B. Y., Croft, R. J., Papafotiou, K., & Stough, C. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0410-7 · Cited by 140
Coffin, P. O., Santos, G.-M., Hern, J., Vittinghoff, E., Walker, J. E., Matheson, T., Santos, D., Colfax, G., & Batki, S. L. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.3655 · Cited by 139
Johnson, B. A., Ait-Daoud, N., Elkashef, A. M., Smith, E. V., Kahn, R., Vocci, F., Li, S.-H., Bloch, D. A., & the Methamphetamine Study Group (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707007778 · Cited by 131
Amphetamine Withdrawal: I. Reliability, Validity and Factor Structure of a Measure
Srisurapanont, M., Jarusuraisin, N., & Jittiwutikan, J. (1999) · Australian & New Zealand Journal of Psychiatry · doi:10.1046/j.1440-1614.1999.00517.x · Cited by 126
Topiramate for the treatment of methamphetamine addiction: a multi‐center placebo‐controlled trial
Elkashef, A. M., Kahn, R., Yu, E., Iturriaga, E., Li, S., Anderson, A., Chiang, N., Ait‐Daoud, N., Weiss, D., McSherry, F., et al. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03771.x · Cited by 122
Longo, M., Wickes, W., Smout, M., Harrison, S., Cahill, S., & White, J. M. (2010) · Addiction · doi:10.1111/j.1360-0443.2009.02717.x · Cited by 122
Treatment for amphetamine withdrawal
Shoptaw, S. J., Kao, U., Heinzerling, K., & Ling, W. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003021.pub2 · Cited by 120 · cited 5×
“Our review also identified several other studies published since the Cochrane Review reporting on withdrawal.”
BackgroundResultInfluentialModafinil for the treatment of methamphetamine dependence
Anderson, A. L., Li, S.-H., Biswas, K., McSherry, F., Holmes, T., Iturriaga, E., Kahn, R., Chiang, N., Beresford, T., Campbell, J., et al. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.07.007 · Cited by 117
Galloway, G., Buscemi, R., Coyle, J., Flower, K., Siegrist, J. D., Fiske, L. A., Baggott, M. J., Li, L., Polcin, D. L., Chen, C. A., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.307 · Cited by 114
Naltrexone Implant for the Treatment of Polydrug Dependence: A Randomized Controlled Trial
Tiihonen, J., Krupitsky, E. M., Verbitskaya, E. V., Blokhina, E. A., Mamontova, O., Föhr, J., Tuomola, P., Kuoppasalmi, K. I., Kiviniemi, V. V., & Zvartau, E. E. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11071121 · Cited by 107
Heinzerling, K. G., Swanson, A.-N., Kim, S., Cederblom, L., Moe, A., Ling, W., & Shoptaw, S. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.11.023 · Cited by 105
Heinzerling, K. G., SHOPTAW, S. J., Peck, J. A., Yang, X., Liu, J., Roll, J. M., & Ling, W. W. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.03.019 · Cited by 103
Grant, J. E., Odlaug, B. L., & Kim, S. W. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.06.018 · Cited by 94
Predicting in-treatment performance and post-treatment outcomes in methamphetamine users.
Hillhouse, M. P., Marinelli-Casey, P., Gonzales, R., Ang, A., & Rawson, R. (2007) · Addiction · doi:10.1111/j.1360-0443.2007.01768.x · Cited by 90
Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder
Ling, W. W., Chang, L., Hillhouse, M. P., Ang, A., Striebel, J. M., Jenkins, J., Hernandez, J. C., Olaer, M., Mooney, L. J., Reed, S. W., et al. (2014) · Addiction · doi:10.1111/add.12608 · Cited by 89
Global Methamphetamine Trends: An Evolving Problem
Stoneberg, D. M., Shukla, R. K., & Magness, M. B. (2018) · International Criminal Justice Review · doi:10.1177/1057567717730104 · Cited by 81
Comparison of intranasal methamphetamine and d‐amphetamine self‐administration by humans
Kirkpatrick, M. G., Gunderson, E. W., Johanson, C., Levin, F. R., Foltin, R. W., & Hart, C. L. (2012) · Addiction · doi:10.1111/j.1360-0443.2011.03706.x · Cited by 78
Cognitive-behavioural treatment for amphetamine-type stimulants (ATS)-use disorders
Harada, T., Tsutomi, H., Mori, R., & Wilson, D. B. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011315.pub2 · Cited by 76 · cited 1×
“Psychosocial therapies have been trialled for AMPH/MA dependence with varying efficacy [14, 15].”
BackgroundA placebo‐controlled trial of mirtazapine for the management of methamphetamine withdrawal
CRUICKSHANK, C. C., MONTEBELLO, M. E., DYER, K. R., QUIGLEY, A., BLASZCZYK, J., TOMKINS, S., & SHAND, D. (2008) · Drug and Alcohol Review · doi:10.1080/09595230801935672 · Cited by 74
Anderson, A. L., Li, S.-H., Markova, D., Holmes, T. H., Chiang, N., Kahn, R., Campbell, J., Dickerson, D. L., Galloway, G. P., Haning, W., et al. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.01.036 · Cited by 70
Coffin, P. O., Santos, G., Das, M., Santos, D. M., Huffaker, S., Matheson, T., Gasper, J., Vittinghoff, E., & Colfax, G. N. (2013) · Addiction · doi:10.1111/add.12073 · Cited by 67
Mousavi, S. G., Sharbafchi, M. R., Salehi, M., Peykanpour, M., Sichani, N. K., & Maracy, M. R. (2015) · PubMed · Cited by 67
Heinzerling, K. G., Swanson, A., Hall, T. M., Yi, Y., Wu, Y., & Shoptaw, S. J. (2014) · Addiction · doi:10.1111/add.12636 · Cited by 64
Winhusen, T. M., Brigham, G. S., Kropp, F., Lindblad, R., Gardin, J. G., Penn, P., Hodgkins, C., Kelly, T. M., Douaihy, A., McCann, M., et al. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08449 · Cited by 64
Miles, S. W., Sheridan, J., Russell, B., Kydd, R., Wheeler, A., Walters, C., Gamble, G., Hardley, P., Jensen, M., Kuoppasalmi, K., et al. (2013) · Addiction · doi:10.1111/add.12109 · Cited by 63
Chiu, C., Ma, T., & Ho, I. K. (2005) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2005.05.028 · Cited by 63
Imipramine for the Treatment of Cocaine and Methamphetamine Dependence
Galloway, G. P., Newmeyer, J., Knapp, T., Stalcup, S. A., & Smith, D. (1995) · Journal of Addictive Diseases · doi:10.1300/j069v13n04_08 · Cited by 55
Mirtazapine in amphetamine detoxification: a placebo-controlled pilot study
Kongsakon, R., Papadopoulos, K. I., & Saguansiritham, R. (2005) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000166815.83017.d8 · Cited by 53
Rezaei, F., Emami, M., Zahed, S., Morabbi, M.-J., Farahzadi, M., & Akhondzadeh, S. (2015) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/s40199-015-0092-y · Cited by 51
Sulaiman, A. H., Gill, J. S., Said, M. A., Zainal, N. Z., Hussein, H. M., & Guan, N. C. (2013) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2012.667116 · Cited by 47
Coffin, P. O., Santos, G., Hern, J., Vittinghoff, E., Santos, D., Matheson, T., Colfax, G., & Batki, S. L. (2018) · Addiction · doi:10.1111/add.13950 · Cited by 46
Wodarz, N., Krampe-Scheidler, A., Christ, M., Fleischmann, H., Looser, W., Schoett, K., Vilsmeier, F., Bothe, L., Schaefer, C., & Gouzoulis‐Mayfrank, E. (2017) · Pharmacopsychiatry · doi:10.1055/s-0042-123752 · Cited by 43
Nicotine and methamphetamine share discriminative stimulus effects
Gatch, M. B., Flores, E., & Forster, M. J. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.08.020 · Cited by 40
Kohno, M., Dennis, L. E., McCready, H. D., Schwartz, D. L., Hoffman, W. F., & Korthuis, P. T. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.07.045 · Cited by 39
Lee, N., Pennay, A. E., Hester, R., McKetin, R., Nielsen, S., & Ferris, J. (2012) · Drug and Alcohol Review · doi:10.1111/j.1465-3362.2012.00473.x · Cited by 35
Double‐blind placebo‐controlled evaluation of the PROMETA™ protocol for methamphetamine dependence
Ling, W., Shoptaw, S., Hillhouse, M., Bholat, M. A., Charuvastra, C., Heinzerling, K., Chim, D., Annon, J., Dowling, P. T., & Doraimani, G. (2012) · Addiction · doi:10.1111/j.1360-0443.2011.03619.x · Cited by 35
Ahmadi, J., & Jahromi, L. R. (2017) · Trials · doi:10.1186/s13063-017-2007-3 · Cited by 34
Ma, J. Z., Johnson, B. A., Yu, E., Weiss, D., McSherry, F., Saadvandi, J., Iturriaga, E., Ait‐Daoud, N., Rawson, R. A., Hrymoc, M., et al. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.10.009 · Cited by 33 · cited 1×
“359 Pharmacological Treatment of Methamphetamine/Amphetamine Dependence in a latent class analysis [69], suggesting further studies with different eligibility criteria are warranted.”
BackgroundRezaei, F., Ghaderi, E., Mardani, R., Hamidi, S., & Hassanzadeh, K. (2016) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12178 · Cited by 32
Morabbi, M.-J., Razaghi, E., Moazen-Zadeh, E., Safi-Aghdam, H., Zarrindast, M. R., Vousoghi, N., & Akhondzadeh, S. (2018) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000200 · Cited by 32
The Effect of Buprenorphine on Methamphetamine Cravings
Salehi, M., Emadossadat, A., Kheirabadi, G. R., Maracy, M. R., & Maracy, M. R. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000408 · Cited by 31
Effect of long term amineptine treatment on pre‐ and postsynaptic mechanisms in rat brain
Ceci, A., Garattini, S. K., Gobbi, M., & Mennini, T. (1986) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1986.tb09495.x · Cited by 27
Rúnarsdóttir, V. Á., Hansdóttir, I., Tyrfingsson, Þ., Einarsson, M., Dugosh, K. L., Royer-Malvestuto, C., Pettinati, H. M., Khalsa, J. H., & WOODY, G. E. (2017) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000297 · Cited by 27
Pilot Randomized Trial of Bupropion for Adolescent Methamphetamine Abuse/Dependence
Heinzerling, K. G., Gadzhyan, J., van Oudheusden, H., Rodriguez, F., McCracken, J. T., & SHOPTAW, S. J. (2013) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2012.10.275 · Cited by 26
Schottenfeld, R. S., Chawarski, M. C., Sofuoglu, M., Chooi, W.-T., Zaharim, N. M., Yasin, M. A. M., Ahmad, I., Jaapar, S. Z. S., & Vicknasingam, B. K. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.01.017 · Cited by 25
Dépendance à la méthamphétamine : de nombreuses conséquences et complications
Karila, L., Petit, A., Cottencin, O., & Reynaud, M. (2010) · La Presse Médicale · doi:10.1016/j.lpm.2010.09.003 · Cited by 24
Urschel, H. C., Hanselka, L. L., & Baron, M. I. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109349837 · Cited by 22
Farahzadi, M.-H., Moazen-Zadeh, E., Razaghi, E., Zarrindast, M.-R., Bidaki, R., & Akhondzadeh, S. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881118817166 · Cited by 18
McKetin, R., Dean, O. M., Turner, A., Kelly, P. J., Quinn, B., Lubman, D. I., Dietze, P., Carter, G. L., Higgs, P., Baker, A., et al. (2019) · Trials · doi:10.1186/s13063-019-3450-0 · Cited by 18
Briones, M., Shoptaw, S., Cook, R., Worley, M., Swanson, A.-N., Moody, D. E., Fang, W. B., Tsuang, J., Furst, B., & Heinzerling, K. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.04.023 · Cited by 17
Ezard, N., Dunlop, A. J., Hall, M., Ali, R. L., McKetin, R., Bruno, R., Phung, N., Carr, A. D., White, J. M., Clifford, B., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020723 · Cited by 16
Self-citationJittiwutikan, J., Srisurapanont, M., & Jarusuraisin, N. (1997) · PubMed · Cited by 13
Amineptine: its effect on the dopaminergic system of rats
Ponzio, F., Achilli, G., Garattini, S. K., Perego, C., Sacchetti, G., & Algeri, S. (1986) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1986.tb04572.x · Cited by 10
Management of withdrawal from alcohol and other drugs
Lintzeris, N., Sunjic, S., Demirkol, A., Branezac, M., Ezard, N., Siefried, K. J., Acheson, L. S., Bascombe, F., Tremonti, C., & Haber, P. (2019) · doi:10.57022/mjjp9930 · Cited by 10
Self-citation
Research works printed but not linked: 5
- World Health Organization. ICD-11: International classification of diseases for mortality and morbidity statistics: 11th rev. Geneva: World Health Organisation; 2018.
- United Nations Office on Drugs and Crime. Treatment of stimulant use disorder: Current practices and promising perspectives. Vienna: United Nations Office on Drugs and Crime; 2019.
- Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. www.covidence.org.
- Center for Behavioral Health Statistics and Quality. Results from the 2016 national survey on drug use and health: detailed tables. Rockville: Substance Abuse and Mental Health Services Administration; 2017.
- Australian Institute of Health and Welfare. National drug strategy household survey 2016: detailed findings. Canberra: Australian Institute of Health and Welfare; 2017.
Cited by
Bupropion and naltrexone in methamphetamine use disorder
Trivedi, M. H., Walker, R., Ling, W., dela Cruz, A., Sharma, G., Carmody, T., Ghitza, U. E., Wahle, A., Kim, M., Shores-Wilson, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2020214 · Cited by 281
Berríos‐Cárcamo, P., Quezada, M., Quintanilla, M. E., Morales, P., Ezquer, M., Herrera‐Marschitz, M., Israel, Y., & Ezquer, F. E. (2020) · Antioxidants · doi:10.3390/antiox9090830 · Cited by 121
“Treatments against the abuse of other drugs have been shown to be ineffective [11] or inconclusive [12].”
BackgroundPharmacotherapeutic strategies for treating cocaine use disorder—what do we have to offer?
Brandt, L., Chao, T. W.-C., Comer, S. D., & LEVIN, F. R. (2020) · Addiction · doi:10.1111/add.15242 · Cited by 94
Turner, D., Briken, P., Grubbs, J., Malandain, L., Mestre-Bach, G., Potenza, M. N., & Thibaut, F. (2022) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2022.2134739 · Cited by 86
The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
(2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001299 · Cited by 78
Metadata
- Authors
- Siefried, K. J., Acheson, L. S., Lintzeris, N., & Ezard, N.
- Affiliations
- UNSW Sydney (AU)
- St Vincent's Hospital Sydney (AU)
- The University of Sydney (AU)
- Corresponding author
- Siefried, Krista J.
- Venue
- CNS Drugs
- Published
- 2020-03-17
- Volume
- 34
- Issue
- 4
- Pages
- 337-365
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- PMC
- PMC7125061
- OpenAlex
- W3010839704
- Semantic Scholar
- c6abc4f20be8eb30ef85f0d999db84d5387a80c2
- Cited by
- 194
- References
- 84
- Citations by year
- 2026: 17 · 2025: 42 · 2024: 32 · 2023: 29 · 2022: 38 · 2021: 31 · 2020: 5
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- CNS Drugs (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- Funders
- Department of Health, Australian Government
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- methamphetamine dependence, amphetamine dependence, pharmacotherapy, d-amphetamine, methylphenidate, naltrexone, topiramate, bupropion, mirtazapine, riluzole, antidepressants, selective serotonin reuptake inhibitors, tricyclic antidepressants, men who have sex with men
- MeSH terms
- Amphetamine, Central Nervous System Stimulants, Animals, Humans, Methamphetamine, Substance-Related Disorders, Amphetamine-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
